EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transcriptional Profiling Reveals Lineage-Specific Characteristics in ATR/CHK1 Inhibitor-Resistant Endometrial Cancer

Tzu-Ting Huang iD, Jung-Min Lee

Biomolecules · 2026

DOI: 10.3390/biom16010169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2026. Verfasst von Tzu-Ting Huang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Checkpoint Kinase 1, Protein Kinase Inhibitors, Drug Resistance, Neoplasm. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recurrent endometrial cancer (EC) has limited therapeutic options beyond platinum-based chemotherapy, highlighting the need to identify exploitable molecular vulnerabilities. Tumors with high genomic instability, including microsatellite instability-high (MSI-h) or copy-number-high (CNH) ECs, rely on the ATR-CHK1 signaling pathway to tolerate replication stress and maintain genome integrity, making this pathway an attractive therapeutic target. However, acquired resistance to ATR and CHK1 inhibitors (ATRi/CHK1i) often develops, and the transcriptomic basis of this resistance in EC remains unknown. Here, we established isogenic ATRi- and CHK1i-resistant cell line models from MSI-h (HEC1A) and CNH (ARK2) EC lineages and performed baseline transcriptomic profiling to characterize stable resistance-associated states. MSI-h-derived resistant clones adopted a unified transcriptional state enriched for epithelial-mesenchymal transition, cytokine signaling, and interferon responses, while ATRi-resistant models showing additional enrichment of developmental and KRAS/Notch-associated pathways. In contrast, CNH-derived resistant clones diverged by inhibitor class, with ATRi resistance preferentially enriching proliferation-associated pathways and CHK1i resistance inducing interferon signaling. Notably, THBS1, EDN1, and TENM2 were consistently upregulated across all resistant models relative to parental lines. Together, these findings demonstrate that acquired resistance to ATRi and CHK1i in EC is shaped by both lineage and inhibitor class and provide a transcriptomic framework that may inform future biomarker development and therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsCheckpoint Kinase 1Protein Kinase InhibitorsDrug Resistance, NeoplasmAtaxia Telangiectasia Mutated ProteinsHumansFemaleGene Expression ProfilingCell Line, TumorGene Expression Regulation, NeoplasticSignal Transduction

Stichwörter der Autor:innen

ATRCHK1drug resistanceendometrial cancer

Substanzen

Checkpoint Kinase 1CHEK1 protein, humanProtein Kinase InhibitorsATR protein, humanAtaxia Telangiectasia Mutated Proteins

Autor:innen und Institutionen

  • Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

ORCID-Profile: Tzu-Ting Huang

Förderung

  • Intramural NIH HHS
  • Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health

Zitieren

APA

Huang, T. T., & Lee, J. M. (2026). Transcriptional Profiling Reveals Lineage-Specific Characteristics in ATR/CHK1 Inhibitor-Resistant Endometrial Cancer. Biomolecules. https://doi.org/10.3390/biom16010169

Vancouver

Huang TT, Lee JM. Transcriptional Profiling Reveals Lineage-Specific Characteristics in ATR/CHK1 Inhibitor-Resistant Endometrial Cancer. Biomolecules. 2026. doi:10.3390/biom16010169

BibTeX
@article{Huang2026,
  author = {Huang, Tzu-Ting and Lee, Jung-Min},
  title = {Transcriptional Profiling Reveals Lineage-Specific Characteristics in ATR/CHK1 Inhibitor-Resistant Endometrial Cancer},
  journal = {Biomolecules},
  year = {2026},
  doi = {10.3390/biom16010169}
}
Kostenlos starten →